More Articles

Health Canada announces plans to tackle drug shortages Policies & Legislation | Posted 20/09/2013

Health Canada announced on 13 September 2013 plans, which it is hoped will help to address problems the country has been having with shortages of drugs in Canada.

EMA approves biosimilar follitropin alfa and somatropin Biosimilars/News | Posted 20/09/2013

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) announced on 31 July 2013 that it had recommended granting of marketing authorization for a biosim...

Southeast Asian generics market to reach US$3.9 billion by 2016 Generics/General | Posted 20/09/2013

Southeast Asia, with its fast-growing, young population and uninsured majority represent a great opportunity for generics in the pharmaceutical industry, according to Rhett Hemedes, Head of OTC Mar...

Avanir and Wockhardt settle Nuedexta patent dispute Generics/News | Posted 20/09/2013

US-based Avanir Pharmaceuticals (Avanir) announced on 6 September 2013 that it had entered into a settlement agreement with Wockhardt USA, the US subsidiary of India-based generics maker Wockhardt,...

Failed biosimilars company to be sold Biosimilars/News | Posted 20/09/2013

The assets of biosimilars developer Elona Biotechnologies (Elona) will be auctioned on 27 September 2013 unless sold before 6 September 2013.

EC approves first monoclonal antibody biosimilar Biosimilars/News | Posted 13/09/2013

Hospira announced on 10 September 2013 that it had received European Commission (EC) approval for its biosimilar monoclonal antibody infliximab (Inflectra), a first in Europe.

South Africa introduces new patent policy Policies & Legislation | Posted 13/09/2013

South Africa has become the latest country to examine its patent laws with a view to curbing patent evergreening and increasing production of generics.

California Assembly passes biosimilars substitution bill Policies & Legislation | Posted 13/09/2013

California has taken a step closer to adopting legislation which would authorize pharmacists to substitute an FDA-approved biosimilars for their reference biologicals with a notification to prescri...